Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: A 10-year follow-up study

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 801-806

  Batty, Nicolas ^a   Hagemeister, Fredrick B ^a   Feng, Lei ^b   Romaguera, Jorge E ^a   Rodriguez, Maria A ^a   McLaughlin, Peter ^a   Samaniego, Felipe ^a   Copeland, Amanda ^a   Dabaja, Bouthaina S ^b   Younes, Anas ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

chemotherapeutic approaches; Lymphoma and Hodgkin disease; T cell mediated immunity

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; LUNG TOXICITY; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THERAPY EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INTERFERONS; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84859983559     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631160     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J. Clin. 2009;59:225-249.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60:277-300.
3. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Hodgkin lymphoma. Available from: Http://seer.cancer.gov/statfacts/html/hodg.html .
4. Horning S, Fanale M, deVos S, et al. Defi ning a population of Hodgkin lymphoma patients for novel therapeutics: An international eff ort. Ann Oncol 2008;19(Suppl. 4): Abstract 118.
5. Haluska FG, Brufsky AM, Canellos GP, et al. The cellular biology of the Reed-Sternberg cell. Blood 1994;84:1005-1019. (Pubitemid 24245862)
6. Smith CA, Farrah T, Goodwin G. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994;76:959-962. (Pubitemid 24106376)
7. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defi nes an emerging family of cytokines with homology to TNF. Cell 1993;73: 1349-1360. (Pubitemid 23201148)
8. Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992;326: 678-687.
9. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
10. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J. Clin. Oncol 2003;21:607-614. (Pubitemid 46621893)
11. Horning SJ, Merigan TC, Krown SE, et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer 1985;56:1305-1310. (Pubitemid 15230573)
12. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferonalfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329:1608-1614. (Pubitemid 23345639)
13. Wedgwood A, Fanale M, Fayad L, et al. Rituximab- ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. Blood 2007;110(Suppl. 1): Abstract 215.
14. Jaff e ES, Harris NL, Stein H, editors. World Health Organization classifi cation of tumours - pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2001.
15. Lister TA, Crowther D, Sutcliff e SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J. Clin. Oncol 1989;7:1630-1636. (Pubitemid 19272832)
16. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297. (Pubitemid 34627193)
17. Cheson BD, Pfi stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol 2007;25:579-586. (Pubitemid 350002966)
18. Mazza P, Tura S, Bocchia M, et al. Alpha-2b recombinant interferon (Intron) in Hodgkin's lymphoma: Therapeutic perspective. Eur J Haematol Suppl 1990;52:22-24. (Pubitemid 20375384)
19. Takeyama H, Yano K, Fukutani H, et al. A preliminary study of chemo-interferon therapy in malignant lymphoma. Gan To Kagaku Ryoho 1987;14:140-145. (Pubitemid 17017405)
20. Coiffi er B, Neidhardt-Bérard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 1999;10: 1191-1197. (Pubitemid 29533569)
21. Renault F, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147: 1577-1580. (Pubitemid 17138838)
22. Copeland A, Cao Y, Fanale M, et al. Final report of a phase II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma: Results of long follow-up and comparison to institutional historical data. Blood 2009;114(Suppl. 1): Abstract 1680.
23. Younes A, McLaughlin P, Fayad L, et al. Six weekly doses of rituximab plus ABVD for newly diagnosed patients with advanced stage classical Hodgkin lymphoma: Depletion of reactive B-cells from the microenvironment by rituximab. Blood 2005;106(Suppl. 1): Abstract 1499.
24. Younes A, Fayad L, Goy A, et al. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: Improvement of event-free survival (EFS) in all International Prognostic Score (IPS) groups. Blood 2006;108(Suppl. 1): Abstract 2742.
25. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
26. Oki Y, Younes A. Does rituximab have a place in treating classic Hodgkin lymphoma? Curr Hematol Malig Rep 2010;5:135-139.
27. Yazbeck V, Georgakis GV, Wedgwood A, et al. Hodgkin's lymphoma: Molecular targets and novel treatment strategies. Future Oncol 2006;2:533-551. (Pubitemid 44304612)